Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJohnson Matthey Regulatory News (JMAT)

Share Price Information for Johnson Matthey (JMAT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,804.00
Bid: 1,813.00
Ask: 1,816.00
Change: 14.00 (0.78%)
Spread: 3.00 (0.165%)
Open: 1,788.00
High: 1,827.00
Low: 1,770.00
Prev. Close: 1,790.00
JMAT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sale of Advanced Glass Technologies

24 Nov 2021 07:00

RNS Number : 3397T
Johnson Matthey PLC
24 November 2021
 

24th November 2021

 

Johnson Matthey Plc

(the Company)

Johnson Matthey announces sale of Advanced Glass Technologies

 

 

· Johnson Matthey announces the sale of its Advanced Glass Technologies business to Fenzi Holdings SPV S.p.A for £178 million on a cash free debt free basis.

 

· Completion anticipated in spring 2022.

 

Johnson Matthey (JM) today announces the sale of its Advanced Glass Technologies (AGT) business, a leading global provider of specialist glass enamels and precious metal pastes supplied mainly to the automotive sector. AGT is part of Value Businesses in JM's 'Other Markets' segment and was previously identified as non-core to JM's growth strategy.

 

AGT will be sold to Fenzi Holdings SPV S.p.A ("Fenzi Group"), a manufacturer and supplier of materials for flat glass processing, for £178 million payable in cash at completion on cash free, debt free basis and subject to customary completion accounts adjustments.

 

The transaction is subject to works council consultation in the Netherlands and the satisfaction of customary completion conditions with completion expected in spring 2022.

 

In the year ended 31st March 2021, AGT generated sales excluding precious metals of £66 million, operating profit of £17 million and gross asset of £49 million. A profit on sale in excess of £100 million is expected. In line with our capital allocation framework, we will return the sale proceeds to shareholders as part of the £200 million share buyback programme commencing in the New Year.

 

The divestment of AGT is consistent with our aim of creating a simpler, more focused portfolio. Aligned with JM's strategy, the company is focusing its resources towards growth areas targeted at climate change solutions as it delivers on its vision for a cleaner, healthier world.

 

 

About Johnson Matthey

Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, we improve the performance, function and safety of our customers' products. Our science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet's natural resources. Today more than 15,000 Johnson Matthey professionals collaborate with our network of customers and partners to make a real difference to the world around us. For more information, visit www.matthey.com

 

 

ENDS

 

Enquiries: 

 

 

 

Investor Relations

Martin Dunwoodie

Louise Curran

Jane Crosby

 

Director of Investor Relations

Senior Investor Relations Manager

Investor Relations Manager

 

020 7269 8241

020 7269 8235

020 7269 8242

 

Media

Barney Wyld

Harry Cameron

 

 

Group Corporate Affairs Director

Tulchan Communications

 

 

020 7269 8001

07799 152 148

 

 

 

 

 

 

Johnson Matthey Plc is listed on the London Stock Exchange (JMAT)

Registered in England & Wales number: 00033774Legal Entity Identifier number: 2138001AVBSD1HSC6Z10 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISBXLLLFFLLFBL
Date   Source Headline
3rd May 20243:31 pmRNSHolding(s) in Company
2nd May 20249:00 amRNSHolding(s) in Company
22nd Apr 20243:39 pmRNSHolding(s) in Company
18th Apr 20245:33 pmRNSDirector/PDMR Shareholding
17th Apr 20243:07 pmRNSHolding(s) in Company
10th Apr 20243:10 pmRNSHolding(s) in Company
10th Apr 20249:47 amRNSHolding(s) in Company
9th Apr 20249:00 amRNSHolding(s) in Company
8th Apr 20249:00 amRNSHolding(s) in Company
3rd Apr 20245:16 pmRNSHolding(s) in Company
2nd Apr 20249:01 amRNSHolding(s) in Company
2nd Apr 20249:00 amRNSHolding(s) in Company
27th Mar 20241:46 pmRNSHolding(s) in Company
22nd Mar 20243:11 pmRNSHolding(s) in Company
21st Mar 202412:13 pmRNSDirector/PDMR Shareholding
20th Mar 20247:00 amRNSJohnson Matthey sale of Medical Device Components
18th Mar 20243:05 pmRNSHolding(s) in Company
18th Mar 20242:32 pmRNSHolding(s) in Company
12th Mar 20245:12 pmRNSHolding(s) in Company
12th Mar 20249:00 amRNSHolding(s) in Company
11th Mar 20249:00 amRNSHolding(s) in Company
7th Mar 20244:20 pmRNSHolding(s) in Company
22nd Feb 20244:53 pmRNSDirector/PDMR Shareholding
20th Feb 20243:57 pmRNSHolding(s) in Company
19th Feb 20243:12 pmRNSHolding(s) in Company
15th Feb 20249:54 amRNSDirector/PDMR Shareholding
9th Feb 20244:17 pmRNSHolding(s) in Company
9th Feb 202412:31 pmRNSDirector/PDMR Shareholding
8th Feb 20242:17 pmRNSHolding(s) in Company
1st Feb 20244:08 pmRNSHolding(s) in Company
29th Jan 20243:22 pmRNSHolding(s) in Company
29th Jan 20242:37 pmRNSHolding(s) in Company
29th Jan 20242:35 pmRNSHolding(s) in Company
23rd Jan 20244:47 pmRNSHolding(s) in Company
19th Jan 20242:18 pmRNSHolding(s) in Company
18th Jan 20242:30 pmRNSHolding(s) in Company
18th Jan 202411:54 amRNSDirector/PDMR Shareholding
10th Jan 20241:29 pmRNSHolding(s) in Company
9th Jan 20241:31 pmRNSHolding(s) in Company
5th Jan 20244:50 pmRNSHolding(s) in Company
4th Jan 20244:26 pmRNSHolding(s) in Company
2nd Jan 20243:27 pmRNSHolding(s) in Company
28th Dec 20231:35 pmRNSHolding(s) in Company
21st Dec 20231:25 pmRNSDirector/PDMR Shareholding
19th Dec 20232:29 pmRNSHolding(s) in Company
15th Dec 20239:00 amRNSHolding(s) in Company
13th Dec 20233:01 pmRNSHolding(s) in Company
11th Dec 20234:20 pmRNSHolding(s) in Company
7th Dec 20231:41 pmRNSHolding(s) in Company
6th Dec 20231:52 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.